Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin studies this year.

Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through his support of Retro Biosciences, a San Francisco-based biotech startup. The company is currently in the process of raising $1 billion in a Series A funding round,

Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in funding to support its research. The Financial Times today cited sources as saying that Sam Altman is participating in the investment. He previously provided the initial $180 million funding round that helped launch Retro.

Altman and Musk were OpenAI’s founding co-chairs in 2015, but their relationship has devolved into name-calling and lawsuits.

Tensions between technology leaders Elon Musk and OpenAI CEO Sam Altman were on full display this week after the Tesla CEO slammed the new artificial intelligence (AI) infrastructure project,

Trump staffers are reportedly angry with Elon Musk for publicly undermining the $500 billion Stargate Project. Musk has questioned the finances behind the AI infrastructure project and used his social media influence to attack one of the project's leaders.